FDAsafety guidance65% confidence
FDA AP — RANLUSPEC (ORIG)
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Lupin.
Regulatory Analysis
Application BLA761480. Sponsor: LUPIN LIMITED. Submission status: AP. Submission type: ORIG. Review priority: STANDARD. Active ingredients: RANIBIZUMAB-HKDZ.
Supporting Context
- Therapeutic area
- Women's Health · Contraception
- Sub-indication
- General
Related signal: Lupin's ANDA091440 for Levonorgestrel and Ethinyl Estradiol Receives AP Status